

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnosics Advisory Committee (DAC)

### Minutes of the Meeting on Wednesday 19 October 2016

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

#### **PRESENT:**

#### **Standing committee members:**

Professor Adrian Newland (Chairman)  
Mrs Alexandria Moseley  
Professor Christopher Hyde  
Dr Dermot Neely  
Mr John Hitchman  
Dr Mark Kroese  
Professor Mark Sculpher  
Mr Patrick McGinley  
Professor Ron Akehurst  
Dr Simon Fleming  
Dr Sue Crawford

#### **Standing committee apologies:**

Professor Anthony Wierzbicki  
Dr Jim Gray  
Mr John Bagshaw (conflicted)  
Dr Michael Messenger  
Dr Peter Naylor  
Dr Simon Richards  
Dr Steve Edwards  
Dr Steve Thomas

#### **NICE staff in attendance:**

Mirella Marlow, Programme Director, DAP  
Carla Deakin, Associate Director, DAP  
Jessica Maloney, Technical Analyst, DAP  
Rebecca Albrow, Technical Advisor, DAP  
Frances Nixon, Technical Adviser, DAP  
Robert Fernley, Project Manager, DAP  
Nick Lowe, Administrator, DAP  
Christopher Pomfrett, Technical Adviser, MTEP

**Observing:**

Elaine Chesworth, Medical Technology Implementation Manager, NICE  
Janet Wale, NICE Observer  
Ken Bond, NICE Observer  
Karen Facey, NICE Observer

**1. Introduction to the meeting**

The Chair welcomed Committee members, observers and members of the public.  
Apologies were noted.

**2. Code of conduct for members of the public attending the meeting**

The Chairman explained the code of conduct to the members of the public attending this meeting.

**3. Any other business**

No other business was offered.

**4. Minutes from the last Committee meeting**

The Committee agreed the minutes from the 20 September 2016 Committee meeting.

**5. NICE's advisory body guide to declaring a conflict of interest**

The Chairman drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

**Quantitative faecal immunochemical tests to assess symptomatic people who are at low risk of colorectal cancer in primary care**

**External Assessment Group representatives: Kleijnen Systematic Reviews Ltd**

Isaac Corro Ramos, Health Economics Researcher  
Dr Marie Westwood, Review Manager

**Specialist committee members:**

Mrs Farhat Din, Senior Lecturer & Honorary Consultant Surgeon  
Ian Danks, Lay Specialist Committee Member  
Ian Godber, Consultant Clinical Scientist and Clinical Lead for Biochemistry  
Dr Paul Otoole, Consultant Gastroenterologist,  
Dr Robert Logan, Consultant Gastroenterologist  
Dr Sophie Nelson, General Practitioner

**Specialist committee members apologies:**

Judith Strachan, Consultant Clinical Scientist

**PART 1 AND PART 2 (open and closed parts of the meeting).**

**Part 1 – Open session**

The Chair welcomed representatives from Alpha Laboratories, Mast Group Ltd, R-Biopharm Rhône Ltd and Sysmex.

There were **3** public attendees.

The Chair asked Committee members to declare any relevant interests.

- Mr John Bagshaw declared a personal financial interest; this meant he was unable to take part in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of Quantitative faecal immunochemical tests to assess symptomatic people who are at low risk of colorectal cancer in primary care.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives and external assessment group for their attendance, participation and contribution to the meeting.

**End of Part 1**

**Part 2 – closed session**

Agreement on the content of the Diagnostic Consultation Document (DCD) was discussed by the committee.

**End of Part 2**

**Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay)**

**External Assessment Group representatives: Warwick Evidence**

Professor James Mason, Health Economist

**Specialist Committee members:**

Dr David Partridge, Consultant Microbiologist  
Dr Giovanni Satta, Consultant in medical microbiology and infectious diseases  
Mary Foss, Lay Specialist Committee Member  
Professor Nigel Cunliffe, Medical Microbiologist  
Dr Robert Logan, Consultant Gastroenterologist

**Specialist committee members apologies:**

None

**PART 1 AND PART 2 (open and closed parts of the meeting).**

**Part 1 – Open session**

The Chair welcomed representatives from AusDiagnostics UK Ltd, bioMérieux UK Ltd and Luminex BV.

There was **1** public attendee.

The Chair asked Committee members to declare any relevant interests.

- Mr John Bagshaw declared a personal financial interest; this meant he was unable to take part in the meeting.

The Committee proceeded to discuss the comments made during the public consultation for the Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay) topic.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the

public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

The Chair thanked the manufacturer representatives and external assessment group for their attendance, participation and contribution to the meeting.

## **End of Part 1**

## **Part 2 – closed session**

Agreement on the content of the Diagnostic Guidance Document (DGD) was discussed by the committee.

## **End of Part 2**

## **Date, time and venue of next meeting**

23 November 2016 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BD